Direct Assessment of P-glycoprotein Efflux to Determine Tumor Response to Chemotherapy

Overview

Journal Biochem Pharmacol

Specialties Biochemistry
Pharmacology

Date 2010 Mar 20

PMID 20298675

Citations 15

Authors

Gauri Patwardhan

Vineet Gupta

Juowen Huang

Xin Gu

Yong-Yu Liu

Affiliations

Soon will be listed here.

Abstract

Multidrug resistance is a major impediment to the success of cancer chemotherapy. The overproduced P-glycoprotein that extrudes anticancer drugs from cells, is the most common mechanism detected in multidrug-resistant cancers. Direct measurement of cellular efflux of tumors in vivo, rather than estimation of MDR1 mRNA and P-glycoprotein levels in samples stored or embedded, can functionally characterize the mechanism of drug resistance and determine the choice of anticancer drugs for cancer patients. Herewith, we introduce a new approach to directly determine P-glycoprotein efflux of tumors. Employing Flutax-2 (Oregon green-488 paclitaxel) and fluorescence spectrophotometry, this method has successfully measured cellular transportability including efflux and accumulation in diverse cancer cell lines, tumors and other tissues with high reproducibility. With this method, we have quantitatively determined cellular efflux that is correlated with P-glycoprotein levels and the reversal effects of agents in cell lines of breast, ovarian, cervical and colon cancers, and in tumor-bearing mice. It has sensitively detected these alterations of P-glycoprotein efflux in approximately 5mg tumor or other tissues with high confidence. This direct and quick functional assessment has a potential to determine drug resistance in different types of cancers after surgical resection. Further validation of this method in clinic settings for the diagnosis of drug resistance purpose is needed.

Citing Articles

GALNT14 Involves the Regulation of Multidrug Resistance in Breast Cancer Cells.

Shan J, Liu Y, Wang Y, Li Y, Yu X, Wu C Transl Oncol. 2018; 11(3):786-793.

PMID: 29702465 PMC: 6058006. DOI: 10.1016/j.tranon.2018.04.003.

Synthesis of a Fluorescent Analogue of Paclitaxel That Selectively Binds Microtubules and Sensitively Detects Efflux by P-Glycoprotein.

Lee M, Gao Z, Peterson B Angew Chem Int Ed Engl. 2017; 56(24):6927-6931.

PMID: 28485901 PMC: 5679005. DOI: 10.1002/anie.201703298.

Differential Coupling of Binding, ATP Hydrolysis, and Transport of Fluorescent Probes with P-Glycoprotein in Lipid Nanodiscs.

Li M, Nath A, Atkins W Biochemistry. 2017; 56(19):2506-2517.

PMID: 28441502 PMC: 5701749. DOI: 10.1021/acs.biochem.6b01245.

Anti-Neoplastic Cytotoxicity of Gemcitabine-(C-)-[anti-HER2/] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3).

Coyne C, Jones T, Bear R Med Chem (Los Angeles). 2015; 3(2):210-223.

PMID: 26225219 PMC: 4516389. DOI: 10.4172/2161-0444.1000141.

Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative....

Coyne C, Jones T, Bear R Cancer Clin Oncol. 2015; 1(2):49-80.

PMID: 26225190 PMC: 4516052. DOI: 10.5539/cco.v1n2p49.

References

Fairchild C, Ivy S, Whang-Peng J, Rosen N, Israel M, Melera P . Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res. 1987; 47(19):5141-8. View

Wilson T, Johnston P, Longley D . Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets. 2009; 9(3):307-19. DOI: 10.2174/156800909788166547. View

Kessel D, Beck W, Kukuruga D, Schulz V . Characterization of multidrug resistance by fluorescent dyes. Cancer Res. 1991; 51(17):4665-70. View

Zhang J, Ling V . Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation. J Biol Chem. 1991; 266(27):18224-32. View

Lai G, Chen Y, Mickley L, Fojo A, Bates S . P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991; 49(5):696-703. DOI: 10.1002/ijc.2910490512. View

Piwnica-Worms D, Chiu M, Budding M, Kronauge J, Kramer R, Croop J . Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993; 53(5):977-84. View

Arceci R . Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood. 1993; 81(9):2215-22. View

Gottesman M, Pastan I . Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993; 62:385-427. DOI: 10.1146/annurev.bi.62.070193.002125. View

Sela S, Husain S, PEARSON J, Longo D, Rahman A . Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil. J Natl Cancer Inst. 1995; 87(2):123-8. DOI: 10.1093/jnci/87.2.123. View

10.

Kramer R, Weber T, Arceci R, Ramchurren N, Kastrinakis W, Steele Jr G . Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. Br J Cancer. 1995; 71(4):670-5. PMC: 2033717. DOI: 10.1038/bjc.1995.133. View

11.

Homolya L, HOLLO M, Muller M, Mechetner E, Sarkadi B . A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. Br J Cancer. 1996; 73(7):849-55. PMC: 2074264. DOI: 10.1038/bjc.1996.151. View

12.

Yang J, Chin K, Hait W . Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells. Cancer Res. 1996; 56(15):3490-4. View

13.

Punyammalee B, Manoromana S, Purisa W, Chariyalertsak S, Rerkamnuaychok B . Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer. J Med Assoc Thai. 1997; 80 Suppl 1:S162-73. View

14.

Walle U, Walle T . Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos. 1998; 26(4):343-6. View

15.

Gouaze V, Liu Y, Prickett C, Yu J, Giuliano A, Cabot M . Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res. 2005; 65(9):3861-7. DOI: 10.1158/0008-5472.CAN-04-2329. View

16.

Diaz J, Strobe R, Engelborghs Y, Souto A, Andreu J . Molecular recognition of taxol by microtubules. Kinetics and thermodynamics of binding of fluorescent taxol derivatives to an exposed site. J Biol Chem. 2000; 275(34):26265-76. DOI: 10.1074/jbc.M003120200. View

17.

Liu Y, Han T, Giuliano A, Cabot M . Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 2001; 15(3):719-30. DOI: 10.1096/fj.00-0223com. View

18.

Jang S, Wientjes M, Au J . Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest New Drugs. 2001; 19(2):113-23. DOI: 10.1023/a:1010662413174. View

19.

Jang S, Wientjes M, Au J . Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther. 2001; 298(3):1236-42. View

20.

Gottesman M, Fojo T, Bates S . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58. DOI: 10.1038/nrc706. View